ArticleFrontiers in oncology2026
Long-term outcomes and patient profiles following intensity-modulated radio-chemotherapy for nasopharyngeal cancer in a nonendemic region.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overexpression of FOXO1 may suppress proliferation and migration and correlate with tumor immune cells in nasopharyngeal carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nasopharyngeal carcinoma (NPC) is rare in non-endemic regions but poses unique clinical challenges, especially among ethnically diverse populations. This study aimed to evaluate the characteristics, treatment outcomes, and toxicity profiles of NPC patients treated with definitive intensity-modulated radio-chemotherapy (IMRT-CRT) in a non-endemic European center. Methods: We conducted a retrospective analysis of 82 consecutive patients with histologically confirmed NPC treated at Institut Jules Bordet between 2012 and 2024. Patient, tumor, treatment characteristics, survival outcomes, and treatment-related toxicity were evaluated. Survival endpoints were calculated using the Kaplan-Meier method and multivariate Cox regression. Results: The median follow-up was 35 months. Most patients were male (77%), of North African descent (66%), and had non-keratinizing carcinoma (96%). Advanced disease (stage III/IV) was present in 72%, and 78% of tested tumors were EBV-positive. Induction chemotherapy (ICT) and concurrent chemotherapy (CCT) were administered in 32% of patients. At 5 years, actuarial estimates for overall survival (OS), progression-free survival (PFS), locoregional disease-free survival (LRDFS), recurrence-free survival (RFS), and distant disease-free survival (DFS) were 73%, 79%, 86%, 87%, and 87%, respectively. Higher T stage, treatment-related weight loss, positive nodal findings on 3-month FDG-PET-CT, and disease recurrence were associated with worse OS. Acute and late toxicities were generally manageable; however, xerostomia, hypothyroidism, ototoxicity, and weight loss were prevalent. Conclusions: Despite being conducted in a non-endemic region, this study revealed NPC characteristics and outcomes resembling those in endemic populations, likely due to patient demographics. Early metabolic response and nutritional status emerged as critical prognostic factors, highlighting the need for individualized treatment and supportive care strategies in NPC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.